FGF19 and colonic neoplasm: Another study in human colon cancer cell lines indicates that when FGF19 interacts with its receptor FGFR4, there is an increase in phosphorylated glycogen synthase kinase 3β (GSK3β), an intermediary of Wnt pathway, which actives β-catenin, that, in turn, causes loss of β-catenin-E-cadherin binding [65].